SHORT HILLS, N.J.--(BUSINESS WIRE)--June 15, 2006--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC - News) announced today that the company has initiated a Phase I clinical trial of sapacitabine (CYC682), an orally available nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes (MDS). This study follows three Phase I trials in solid tumors or lymphomas involving over 120 patients which evaluated safety and pharmacokinetics of a variety of dosing schedules for future Phase II studies and combination studies with other anti-cancer agents.
